ReviewClinical, cosmetic and investigational dermatology2015
Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.
Review in Clinical, cosmetic and investigational dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.Expert opinion on biological therapy · 2021Trial
- Ligands of CD6: roles in the pathogenesis and treatment of cancer.Frontiers in immunology · 2024Review
- Severe bronchospasm following itolizumab infusion in a COVID-19 patient.Journal of anaesthesiology, clinical pharmacology · 2022Article
- The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.The Journal of clinical investigation · 2022Article
- Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Insights into biological therapeutic strategies for COVID-19.Fundamental research · 2021Review
- Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Article
- Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era.SN comprehensive clinical medicine · 2020Article
- Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena.Frontiers in pharmacology · 2020Review
- The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.Oncotarget · 2019Article
- Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India.Psoriasis (Auckland, N.Z.) · 2019Review
- Article
- Targeting CD6 for the treatment of experimental autoimmune uveitis.Journal of autoimmunity · 2018Article
- Itolizumab in the Management of Psoriasis with Metabolic Syndrome.Journal of clinical and diagnostic research : JCDR · 2017Article
- CD6 as a potential target for treating multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Safety and Efficacy of Itolizumab in the Treatment of Psoriasis: A Case Series of 20 Patients.Journal of clinical and diagnostic research : JCDR · 2016Article
- Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions.Dermatology research and practice · 2016Article
- Anti CD-6 Monoclonal Antibodies in the Management of Generalised Pustular Psoriasis.Indian journal of dermatologyArticle
- Biologics and Biosimilars in Psoriasis.Indian journal of dermatologyArticle
- A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis.Indian dermatology online journalArticle
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of psoriasis is a challenge to the treating physician. The chronic inflammatory state of psoriasis with exacerbations and remissions necessitate "on-and-off" treatment schedules. The safety profiles of drugs and tolerability issues for patients are important factors to be considered during treatment. Various biological agents targeting T-cells and the inflammatory cytokines are available for systemic treatment of psoriasis. However, major causes of concern while using these drugs are risk of susceptibility to infection and development of anti-drug antibodies, which will affect the pharmacokinetic properties, efficacy, and safety profile of the drug. Itolizumab, a humanized anti-CD6 monoclonal antibody, is a new molecule that acts by immunomodulating the CD6 molecule. CD6 is a co-stimulatory molecule required for optimal T-cell stimulation by the antigen-presenting cells. This step is crucial in T-cell proliferation to form Th1 and Th17 cells, which play a major role in the pathogenesis of psoriasis. This article deals with the properties of Itolizumab and its role in the treatment of psoriasis. Based on the available published data, Itolizumab seems to have a better adverse effects profile and at the same time comparatively less efficacy when compared to other biological agents available for treating psoriasis. Larger studies with longer duration are required to clearly depict the long-term side effects profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.